Search Results - "Stover, D G"

Refine Results
  1. 1

    Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer by Telli, M. L., Stover, D. G., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., Newman, L., Sledge, G. W., Winer, E. P.

    Published in Breast cancer research and treatment (01-08-2018)
    “…Purpose Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the…”
    Get full text
    Journal Article
  2. 2

    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study by Reichert, Z.R., Morgan, T.M., Li, G., Castellanos, E., Snow, T., Dall’Olio, F.G., Madison, R.W., Fine, A.D., Oxnard, G.R., Graf, R.P., Stover, D.G.

    Published in Annals of oncology (01-01-2023)
    “…Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor…”
    Get full text
    Journal Article
  3. 3

    Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma by Stover, D G, Reddy, V K, Shyr, Y, Savani, B N, Reddy, N

    Published in Bone marrow transplantation (Basingstoke) (01-01-2012)
    “…Early lymphocyte recovery following auto-SCT for non-Hodgkin's lymphoma (NHL) has been reported to be associated with improved outcome. The significance of…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF by Lang, J C, Borchers, J, Danahey, D, Smith, S, Stover, D G, Agrawal, A, Malone, J P, Schuller, D E, Weghorst, C M, Holinga, A J, Lingam, K, Patel, C R, Esham, B

    Published in International journal of oncology (01-08-2002)
    “…Inactivation of the p16 tumor suppressor gene is a common phenomenon in squamous cell carcinoma of the head and neck (SCCHN). Less commonly described is the…”
    Get more information
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Analysis of BRAF and KRAS mutations in colorectal cancer and rectal carcinogenesis via fluorescent allele-specific PCR by Stover, D. G., Cushman-Vokoun, A. M., Vnencak-Jones, C. L., Berlin, J.

    Published in Journal of clinical oncology (01-02-2011)
    “…Abstract only 436 Background: Molecular analysis has become increasingly relevant in the evaluation of colorectal carcinomas. Mutations in Ras-MAPK pathway…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Abstract P3-07-07: Withdrawn by Jiang, Y-Z, Ma, D, Suo, C, Shi, J, Xue, M, Stover, DG, Verschraegen, C, Kaklamani, V, Wang, P, Shi, L, Huang, W, Shao, Z-M

    Published in Cancer research (Chicago, Ill.) (15-02-2019)
    “…Abstract This abstract was withdrawn by the authors. Citation Format: Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Stover DG, Verschraegen C, Kaklamani V, Wang P, Shi…”
    Get full text
    Journal Article
  12. 12

    Abstract P1-07-05: Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and poor prognosis by Stover, DG, Selfors, LM, Winer, EP, Partridge, AH, Barry, WT

    Published in Cancer research (Chicago, Ill.) (15-02-2017)
    “…Abstract Background: In triple-negative breast cancers (TNBC), high proliferation is associated with greater chemosensitivity but, paradoxically, also…”
    Get full text
    Journal Article
  13. 13

    Abstract P4-01-17: Aggressive subgroups of metastatic triple-negative breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort by Singh, J, Asad, S, Nock, W, Zhang, Y, Adams, E, Damicis, A, Parsons, HA, Adalsteinsson, VA, Winer, EP, Lin, NU, Partridge, AH, Overmoyer, B, Stover, DG

    Published in Cancer research (Chicago, Ill.) (15-02-2019)
    “…Abstract Background: Relative to other metastatic breast cancer subtypes, metastatic triple-negative breast cancer (mTNBC) has a shorter duration of response…”
    Get full text
    Journal Article
  14. 14

    Abstract P3-07-08: Multi-omic predictor of rapid and late relapse in primary triple negative breast cancer by Zhang, Y, Nock, W, Asad, S, Adams, E, Singh, J, Damicis, A, Lustberg, MB, Noonan, A, Reinbolt, R, Sardesai, S, VanDeusen, J, Wesolowski, R, Williams, N, Ramaswamy, B, Stover, DG

    Published in Cancer research (Chicago, Ill.) (15-02-2019)
    “…Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease. Clinically, we observe three distinct TNBC outcomes: 1) rapid relapse…”
    Get full text
    Journal Article
  15. 15

    Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab by Waks, AG, Stover, DG, Barry, W, Dillon, D, Gjini, E, Rodig, SJ, Brock, J, Baltay, M, Savoie, J, Winer, EP, Krop, I, Tolaney, SM

    Published in Cancer research (Chicago, Ill.) (15-02-2018)
    “…Abstract Background: Hormone receptor-positive (HR+) tumors have fewer tumor-infiltrating lymphocytes (TILs) and lower response rates to immune checkpoint…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Abstract P3-07-31: Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy by Stover, DG, Waks, AG, Erica, ML, Brugge, JS, Winer, EP, Selfors, LM

    Published in Cancer research (Chicago, Ill.) (15-02-2016)
    “…Abstract Background: Proliferation is the strongest predictor of response to neoadjuvant chemotherapy in estrogen receptor-positive (ER+) breast cancer…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer by Stover, DG, Gil Del Alcazar, CR, Tolaney, SM, Bardia, A, Guo, H, Balko, JM, Overmoyer, BA, Gelman, RS, Lloyd, M, Wang, V, Brock, JE, Winer, EP, Polyak, K, Lin, NU

    Published in Cancer research (Chicago, Ill.) (15-02-2018)
    “…Abstract Background: Preclinical data supports a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer (BC). Ruxolitinib is an orally bioavailable…”
    Get full text
    Journal Article
  20. 20